Eltatsin lingval tab. 30 pc

$5.00

Eltatsin lingval tab. 30 pc

5 in stock

Quantity:

Description

Composition
Active substance:
Glycine – 70mg, glutamic acid – 70 mg, cystine – 70 mg ;.
Excipients:
Methyl cellulose – 7.8 mg magnesium stearate – 2.2 mg.
Description:
Round biconvex white or white with a yellowish tinge.
Product form:
Sublingual tablets, 70 mg + 70 mg + 70 mg. 30 tablets in blisters of PVC film and aluminum foil. 1 contour cellular packaging together with instructions for use in a pile of cardboard.
Contraindications
Hypersensitivity to the drug, children under 11 years (effectiveness and safety have been established).
Indications
Autonomic dysfunction syndrome in adults and children from 12 years.
Prevention of chronic physical overexertion and recovery after intense exercise in sporting activities for children between the ages of 11 to 15 years.
Chronic heart failure I-III NYHA functional class classification in adults (with standard therapy).
Chronic heart failure I-II NYHA functional class classification in children under the age of 12 years (with standard therapy).
Interaction with other drugs
It can be taken together with inhibitors of angiotensin converting enzyme (ACE) inhibitors, beta-blockers, diuretics, aldosterone antagonists, nitrates and organic blockers “slow” calcium channels.
Overdose
Cases of overdose have been identified.
pharmachologic effect
Pharmacological group:
Anti-oxidant agent.
Pharmacodynamics:
Eltatsin® – a combined preparation which comprises a mixture of essential amino acids: glycine, glutamic acid and cystine. Eltatsina® components are regulators of metabolic that increase the intracellular concentration of glutathione and glutathione-dependent enzyme activity, normalizing the redox processes and utilization of oxygen in the tissue, whereby the formulation: exhibits antioxidant (reducing the content of free radicals, peroxy compounds, malondialdehyde) and antihypoxic action (improving resistance to oxygen deficiency, increasing the processes of synthesis of adenosine triphosphate (ATP)); increases myocardial contractility; increases physical performance; It improves the quality of life in patients with chronic heart failure (increasing social inclusion, improving psycho-emotional state); It accelerates the recovery operation after intense exercise in children.
Pharmacokinetics:
Glycine penetrates into most biological fluids and tissues, including in the brain, does not accumulate in the tissues, it is metabolized to carbon dioxide and water. When receiving the glutamic acid is well absorbed, penetrates the blood-brain barrier and cellular membranes. Utilized in the process of metabolism, 4-7% excreted by the kidneys in unchanged form. Upon receiving the cystine concentration is gradually increased, reaching a maximum after 30 minutes and then slowly decreases, cystine is not accumulated is not toxic.
Pregnancy and breast-feeding
Individual studies have been conducted. Not recommended for use during pregnancy and lactation.
Conditions of supply of pharmacies
Without a prescription.
side effects
Allergic reactions.
special instructions
The possibility of influence of the drug on the ability to drive vehicles and other potentially dangerous machines: No effect.
Storage conditions
At temperatures above 25 ° C in its original packaging.
Keep out of the reach of children.
Dosing and Administration
Sublingually. The tablet can be chewed and also hold in the mouth under the tongue until complete dissolution.
Autonomic dysfunction syndrome in adults and children from 12 years: 1 tablet 3 times per day sublingually, treatment 1 to 3 months depending on the severity of the disease, repeated courses are appointed on the recommendation of a doctor.
Prevention of chronic physical overexertion in children aged 11 to 15 years: 1 tablet 2 times daily for 2-3 weeks.
During the period of recovery after intense exercise in sporting activities for children between the ages of 11 to 15 years: 1 tablet 3 times a day for 2 weeks.
Chronic heart failure I-III NYHA functional class classification in adults: 1 tablet 3 times per day sublingually, treatment 1 to 3 months depending on the severity of the disease, repeated courses are appointed on the recommendation of a doctor.
Chronic heart failure I-II NYHA functional class classification in children under the age of 12 years: 1 tablet 3 times per day sublingually, treatment 1 to 3 months depending on the severity of the disease, repeated courses are appointed on the recommendation of a doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

biotics

There are no reviews yet.

Add your review